Systemic lupus erythematosus diagnosis and management

Rheumatology (United Kingdom)

Volumn 56, Issue , 2017, Pages i3-i13

  Thong, Bernard ^a   Olsen, Nancy J ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Antinuclear antibodies; Autoantibodies; Biological therapeutics; Classification criteria; Corticosteroids; Hydroxychloroquine; Immunosuppressive therapy; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; BIOLOGICAL PRODUCT; CORTICOTROPIN; CORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; VITAMIN D; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; BELIMUMAB; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; DNA; GLUCOCORTICOID; MONOCLONAL ANTIBODY; RITUXIMAB;

ADOLESCENT; ARTICLE; CARDIOVASCULAR DISEASE; CHILDHOOD; COMORBIDITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; FOLLOW UP; GERIATRIC PATIENT; HUMAN; LUPUS VULGARIS; MALIGNANT NEOPLASM; METABOLIC SYNDROME X; OFF LABEL DRUG USE; ONSET AGE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PERSONALIZED MEDICINE; PHENOTYPE; PLASMAPHERESIS; PREDICTION; PREGNANCY; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; DISEASE MANAGEMENT; ERYTHROCYTE SEDIMENTATION RATE; IMMUNOLOGY; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; SKIN; VITAMIN D DEFICIENCY;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPLEMENT C3; DISEASE MANAGEMENT; DISEASE PROGRESSION; DNA; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLIC SYNDROME X; OSTEOPOROSIS; RITUXIMAB; SKIN; VITAMIN D DEFICIENCY;

EID: 85021854661     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew401     Document Type: Article

References (135)

1. Tan E, Cohen A, Fries J et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
3. Petri M, Orbai AM, Alarcón GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86
4. Inês L, Silva C, Galindo M et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res 2015;67:1180-5
5. Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Disease. 2nd edn. New York: Igaku-Shoin; 1995
6. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50
7. Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004;51:810-8
8. Borowoy AM, Pope JE, Silverman E et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 2012;42:179-85
9. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003;42:200-13
10. Chai J, Logigian EL. Neurological manifestations of primary Sjogren's syndrome. Curr Opin Neurol 2010;23:509-13
11. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981;4:471-5
12. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 2014;48-49:14-9
13. Kuhn A, Kuehn E, Meuth AM et al. Development of a core set questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2009;8:702-12
14. Kuhn A, Meuth AM, Bein D et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010;163:83-92
15. Ugarte-Gil MF, Alarcón GS. Incomplete systemic lupus erythematosus: early diagnosis or overdiagnosis? Arthritis Care Res 2016;68:285-7
16. Bourn R, James JA. Preclinical lupus. Curr Opin Rheumatol 2015;27:433-9
17. Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther 2013;15:218
18. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556-62
19. Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis 2015;18:182-91
20. Sag E, Tartaglione A, Batu ED et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol 2014;32:440-4
21. Medlin JL, Hansen KE, Fitz SR, Bartels CM. A systematic review and meta-analysis of cutaneous manifestations in late-versus early-onset systemic lupus erythematosus. Semin Arthritis Rheum 2016;45:691-7
22. Tomic-Lucic A, Petrovic R, Radak-Perovic M et al. Lateonset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol 2013;32:1053-8
23. Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. Drugs Aging 2012;29:181-9
24. Gladman DD, Hirani N, Ibañez D, Urowitz MB. Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003;30:1960-2
25. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010;37:1822-7
26. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res 2012;64:511-8
27. Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8
28. Conti F, Ceccarelli F, Perricone C et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year followup study. PLoS One 2012;7:e45934
29. Zen M, Bassi N, Nalotto L et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012;30:856-63
30. Steiman AJ, Urowitz MB, Ibañez D, Papneja A, Gladman DD. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808-16
31. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32:1467-72
32. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21
33. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14 (Suppl 4):S4
34. Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus. Genomics Proteomics Bioinformatics 2015;13:210-8
35. Dozmorov I, Dominguez N, Sestak AL et al. Evidence of dynamically dysregulated gene expression pathways in hyperresponsive B cells from African American lupus patients. PLoS One 2013;8:e71397
36. Banchereau R, Hong S, Cantarel B et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:551-65
37. Kao AH, Navratil JS, Ruffing MJ et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010;62:837-44
38. Fernando MMA, Isenberg DA. How to monitor SLE in routine clinical practice. Ann Rheum Dis 2005;64:524-7
39. Mosca M, Tani C, Aringer M et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011;10:383-8
40. Yazdany J, Panopalis P, Gillis JZ et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009;61:370-7
41. Gillis JZ, Panopalis P, Schmajuk G, Ramsey-Goldman R, Yazdany J. Systematic review of the literature informing the systemic lupus erythematosus indicators project: reproductive health care quality indicators. Arthritis Care Res 2011;63:17-30
42. Hollander MC, Sage JM, Greenler AJ et al. International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2013;65:1416-23
43. Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res 2015;67:1440-52
44. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res 2011;63 (Suppl 11):S37-46
45. van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-totarget in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67
46. Franklyn K, Lau CS, Navarra SV et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615-21
47. Lattanzi B, Consolaro A, Solari N et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI;SDI). Arthritis Care Res 2011;63 (Suppl 11):S112-7
48. Fernandez D, Kirou KA. What causes lupus flares? Curr Rheumatol Rep 2016;18:14
49. Jara LJ, Medina G, Cruz-Dominguez P et al. Risk factors of systemic lupus erythematosus flares during pregnancy. Immunol Res 2014;60:184-92
50. Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg ÁM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. PLoS One 2014;9:e104303
51. Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007;56:3070-9
52. Huong DL, Wechsler B, Vauthier-Brouzes D et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum 2002;32:174-88
53. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013;27:329-40
54. Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH. Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res 2015;67:1712-21
55. Petri MA, van Vollenhoven RF, Buyon J et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143-53
56. McDonagh JE, Shaw KL. Adolescent rheumatology transition care in the UK. Pediatr Ann 2012;41:e8-15
57. Tattersall RS. The MAGICC and practical approach to rheumatology transition. Br J Hosp Med 2012;73:552-7
58. Grein IH, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in systemic lupus erythematosus patients: what we really should know. Pediatr Rheumatol Online J 2016;14:12
59. Son MB, Sergeyenko Y, Guan H, Costenbader KH. Disease activity and transition outcomes in a childhoodonset systemic lupus erythematosus cohort. Lupus 2016;25:1431-1439
60. Felsenstein S, Reiff AO, Ramanathan A. Transition of care and health-related outcomes in pediatric-onset systemic lupus erythematosus. Arthritis Care Res 2015;67:1521-8
61. Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2013;27:435-47
62. Østensen M, Andreoli L, Brucato A et al. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 2015;14:376-86
63. Götestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810
64. Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015;11:301-12
65. Schreiber K. Pregnancies in women with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2016;25:343-5
66. Senn N, Monod S. Development of a comprehensive approach for the early diagnosis of geriatric syndromes in general practice. Front Med 2015;2:78
67. Bertsias GK, Ioannidis JP, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82
68. Lawson EF, Trupin L, Yelin EH, Yazdany J. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. Semin Arthritis Rheum 2015;44:666-71
69. Yun H, Yang S, Chen L et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 2016;68:2328-37
70. Guthridge JM, Cogman A, Merrill JT et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol 2013;40:1875-80
71. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77-95
72. Urowitz MB, Gladman DD, Anderson NM et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med 2016;3:e000143
73. Tselios K, Sheane BJ, Gladman DD, Urowitz MB. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. J Rheumatol 2016;43:54-65
74. Abella V, Scotece M, Conde J et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res 2014;2014:343746
75. Parker B, Bruce I. SLE and metabolic syndrome. Lupus 2013;22:1259-66
76. Muniz LF, Pereira RM, Silva TF, Bonfá E, Borba EF. Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: beneficial effect of antimalarials. Arthritis Care Res 2015;67:1255-62
77. Sinicato NA, Postal M, Peres FA et al. Obesity and cytokines in childhood-onset systemic lupus erythematosus. J Immunol Res 2014;2014:162047
78. Edens C, Robinson AB. Systemic lupus erythematosus, bone health, and osteoporosis. Curr Opin Endocrinol Diabetes Obes 2015;22:422-31
79. Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis. Arthritis Care Res 2010;62:1515-26
80. McClung M. Controversies in osteoporosis management: concerns about bisphosphonates and when are ''drug holidays'' required? Clin Obstet Gynecol 2013;56:743-8
81. Anagnostis P, Stevenson JC. Bisphosphonate drug holidays-when, why and for how long? Climacteric 2015;18 (Suppl 2):32-8
82. Yap KS, Morand EF. Vitamin D and systemic lupus erythematosus: continued evolution. Int J Rheum Dis 2015;18:242-9
83. Fuleihan Gel-H, Bouillon R, Clarke B et al. Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range. J Bone Miner Res 2015;30:1119-33
84. Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 2015;27:454-60
85. Noble PW, Bernatsky S, Clarke AE et al. DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nat Rev Rheumatol 2016;12:429-34
86. Tessier-Cloutier B, Clarke AE, Pineau CA et al. What investigations are needed to optimally monitor for malignancies in SLE? Lupus 2015;24:781-7
87. Pons-Estel GJ, Alarcó n GS, González LA et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res 2010;62:393-400
88. Callen JP. Management of antimalarial-refractory cutaneous lupus erythematosus. Lupus 1997;6:203-8
89. Callen JP. Management of ''refractory'' skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2005;19:767-84
90. Garza-Mayers AC, McClurkin M, Smith GP. Review of treatment for discoid lupus erythematosus. Dermatol Ther 2016;29:274-83
91. Williams HJ, Egger MJ, Singer JZ et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994;21:1457-62
92. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991;324:150-4
93. Arnal C, Piette JC, Léone J et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29:75-83
94. Pons-Estel GJ, Alarcón GS, McGwin G et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009;61:830-9
95. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70
96. Alarcón GS, McGwin G, Bertoli AM et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72
97. Mercer E, Rekedal L, Garg R et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012;14:R135
98. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11:R109
99. Marmor MF, Kellner U, Lai TYY et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016;123:1386-94
100. McCune WJ, Gonzalez-Rivera T. Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity? Curr Opin Rheumatol 2015;27:213-5
101. Soffer LJ, Levitt MF, Baehr G. Use of cortisone and adrenocorticotropic hormone in acute disseminated lupus erythematosus. AMA Arch Intern Med 1950;86:558-73
102. Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007;16:387-93
103. Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun Rev 2006;5:111-3
104. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021-8
105. Bruce IN, O'Keeffe AG, Farewell V et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2015;74:1706-13
106. Lightstone L. Minimising steroids in lupus nephritis-will B cell depletion pave the way? Lupus 2013;22:390-9
107. Adams DA, Gordon A, Maxwell MH. Azathioprine treatment of immunological renal disease. JAMA 1967;199:459-63
108. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975;18:27-34
109. Austin HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9
110. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95
111. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol 2014;77:704-14
112. Kham SK, Soh CK, Liu TC et al. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol 2008;64:373-9
113. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40
114. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus 2007;16:212-6
115. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4
116. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
117. Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797-808
118. Rostas S, Kim M, Gabardi S. Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations. Prog Transplant 2014;24:33-6
119. Muangchan C, van Vollenhoven RF, Bernatsky SR et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res 2015;67:1237-45
120. Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013;15 Suppl 1:S2
121. Condon MB, Ashby D, Pepper RJ et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6
122. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
123. Chong BF, Tseng LC, Kim A et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci 2014;73:216-24
124. Strand V, Levy RA, Cervera R et al. Improvements in health-related quality of life with belimumab, a Blymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014;73:838-44
125. Khamashta M, Merrill JT, Werth VP et al. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909-16
126. Kalunian KC. Interferon-targeted therapy in systemic lupus erythematosus: is this an alternative to targeting B and T cells? Lupus 2016;25:1097-101
127. Kalunian KC, Merrill JT, Maciuca R et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202
128. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 2014;23:225-35
129. Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res 2013;65: 1775-85
130. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015;11:46-61
131. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012;11:321-5
132. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014;66:3096-104
133. Ocampo V, Haaland D, Legault K, Mittoo S, Aitken E. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous. BMJ Case Rep 2016; doi 10.1136/ bcr-2016-215423
134. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000;118:1083-90
135. Ky C, Swasdibutra B, Khademi S et al. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-ofconcept study. Dermatol Reports 2015;7:5804